Key result
Obesity in HFpEF carries specific diagnostic and therapeutic implications based on REDUCE LAP-HF II.
Key points are not available for this paper at this time.
Answers are grounded in this paper and cite their sources.
This article refers to 'Obesity in heart failure with preserved ejection fraction: Insights from the REDUCE LAP-HF II trial' by S.E.
No takes yet. Share an insight, caveat, or question.
Saito et al. (2024) studied this question. Obesity in patients with heart failure with preserved ejection fraction carries specific diagnostic and therapeutic implications based on insights from the REDUCE LAP-HF II trial.
Synapse has enriched 10 related papers. Consider them for comparative context: